New drugs approved by US FDA in 2007 and problems and suggestions

Chinese Journal of New Drugs

Volumn 17, Issue 11, 2008, Pages 988-992

  Tang, Zhong Ming ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Analysis; Approved new drugs; FDA; New molecular entities

Indexed keywords

ALISKIREN; AMBRISENTAN; ANGIOPEPTIN; BYSTOLIC; DALBAVANCIN; DORIBAX; DORIPENEM; ECULIZUMAB; HETASTARCH; IXABEPILONE; IXEMPRA; KUVAN; LAPATINIB; LETAIRIS; LISDEXAMFETAMINE; MARAVIROC; MIRCERA; NEBIVOLOL; NEW DRUG; NILOTINIB; RALTEGRAVIR; RECOMBINANT ERYTHROPOIETIN; RETAPAMULIN; RIMONABANT; ROSIGLITAZONE; ROTIGOTINE; SAPROPTERIN; SOMATULINE DEPOT; TEMSIROLIMUS; UNINDEXED DRUG; VILDAGLIPTIN;

BIOTECHNOLOGY; DRUG APPROVAL; DRUG DETERMINATION; DRUG INDUSTRY; DRUG LEGISLATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; LICENSING; MEDICAL EXPERT; REVIEW; UNITED STATES;

EID: 77953438162     PISSN: 10033734     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (8)

1. HUGHES B. 2007 FDA drug approvals: a year of flux [J]. Nat Rev Drug Discov, 2008, 7 (2): 107-109.
2. Editorial. The regulator disapproves[J]. Nat Biotechnol, 2008, 26 (1): 1.
3. European Medicines Agency (EMEA/H/C/666) EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) ACOMPLIAEPAR summary for the public: European Medicines Agency [EB/OL]. [2007-10-01]. http://www.emea.europa.ea/humandocs/PDFs/ EPAR/acomplia/H-666-enl.pdf.
4. Evaluation of Medicines for Human Use (EMEA/H/C/771) EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) GALVUS EPAR summary for the public [EB/OL]. [2008-02-01]. http://www.emea.europa.eu/humandocs/PDFs/EPAR/galvus/ H-771-enl.pdf.
5. Performance report to the president and the congress for the for the Prescription Drug User Fee Act[EB/OL]. [2008-08-01]. http://www.fda.gov/ ope/pdufa/report2006/PDUFA2006perf.pdf.
6. Food and Drug Administration. FDA Science Board Advisory Committee Meeting[EB/OL]. [2007-12-03]. http://www.fda.gov/ohrms/dockets/ac/07/ briefing/2007-4329b_02_00_index.html.
7. CZEREPAK AE, RYSER S. Drug approvals and failures: implications for alliances[J]. Nat Rev Drug Discov, 2008, [Epub ahead of print].
8. Chinese source.